Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study

被引：2

作者：

Wan, Zhikai ^{[1
]}

Su, Junwei ^{[1
]}

Zhu, Xueling ^{[1
]}

Liu, Xiang ^{[1
]}

Guo, Yongzheng ^{[1
]}

Xiang, Dairong ^{[1
]}

Zhou, Xiaotang ^{[1
]}

Peng, Xiaorong ^{[1
]}

Tao, Ran ^{[1
]}

Cao, Qing ^{[1
]}

Lang, Guanjing ^{[1
]}

Huang, Ying ^{[1
]}

Zhu, Biao ^{[1
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1,Dept Infect Dis,Sch Med, Natl Clin Res Ctr Infect Dis,State Key Lab Diag &, Collaborat Innovat Ctr Diag & Treatment Infect Di, 79 Qingchun Rd, Hangzhou, Zhejiang, Peoples R China

来源：

INFECTIOUS DISEASES AND THERAPY | 2024年 / 13卷 / 04期

关键词：

Lipidomic; HIV; Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Bictegravir/emtricitabine/tenofovir alafenamide; Switch; CARDIOVASCULAR-DISEASE; TENOFOVIR ALAFENAMIDE; LIVER-DISEASE; RISK; INFECTION; EMTRICITABINE; POPULATION; COBICISTAT; MORTALITY; PHASE-3;

D O I：

10.1007/s40121-024-00943-0

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more favorable pharmacokinetics and fewer drug-drug interactions. However, the effect of this switch on plasma lipids and lipidomic profiles remains poorly characterized. Methods: HIV infected patients on an E/C/F/TAF regimen were recruited into the study and followed up every 12 weeks. Participants were divided into E/C/F/TAF and B/F/TAF groups depending on whether they were switched to B/F/TAF during follow-up. Clinical information and blood samples were collected at 0, 12, and 24 weeks, and lipidomic analysis was performed using liquid chromatography mass spectrometry. Results: No significant differences were observed between the groups at baseline. At week 24, patients switched to B/F/TAF had lower triglyceride [mmol/L; 1.23 (0.62) versus 2.03 (0.75), P = 0.001] and very low-density lipoprotein cholesterol [mmol/L; 0.64 (0.26) versus 0.84 (0.32), P = 0.037) compared with patients who continued E/C/F/TAF therapy. Small decrease from baseline in Framingham general cardiovascular risk score (FRS) was observed in the B/F/TAF arm [week (W) 0: 2.59 (1.57) versus W24: 2.18 (1.01), P = 0.043]. Lipidomic analysis indicated that E/C/F/TAF treatment increased the levels of several diglycerides (DGs), triacylglycerols (TAGs), and lyso-phosphatidylcholines (LPCs), whereas switching to B/F/TAF led to increased sphingolipids and glycerophospholipids. After adjusting for demographic and clinical parameters, only DG (16:0/18:2), DG (18:2/22:6), DG (18:3/18:2), DG (20:5/18:2), TAG (18:3/18:2/21:5), TAG (20:5/18:2/22:6), and LPC (22:6) were found to be significantly associated with FRS (regression coefficient of 0.17-6.02, P < 0.05). Most of these FRS associate lipid species were significantly elevated in individuals treated with E/C/F/TAF instead of individuals treated with B/F/TAF. Conclusion: E/C/F/TAF promotes the accumulation of lipid species closely associated with cardiovascular disease (CVD) risk among people living with HIV, whereas B/F/TAF has a decreased impact on CVD-related lipid profile and is associated with lower CVD risk.

引用

页码：727 / 744

页数：18

共 47 条

[1]

AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2021, Zhonghua Nei Ke Za Zhi, V60, P1106, DOI 10.3760/cma.j.cn112138-20211006-00676

[2] Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis [J].

Akerele, O. A. ;

Cheema, S. K. .

MEDICAL HYPOTHESES, 2015, 85 (06) :754-760

[3] Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons [J].

Bowman, Emily R. ;

Kulkarni, Manjusha ;

Gabriel, Janelle ;

Cichon, Morgan J. ;

Riedl, Kenneth ;

Belury, Martha A. ;

Lake, Jordan E. ;

Richardson, Brian ;

Cameron, Cheryl ;

Cameron, Mark ;

Koletar, Susan L. ;

Lederman, Michael M. ;

Sieg, Scott F. ;

Funderburg, Nicholas T. .

FRONTIERS IN IMMUNOLOGY, 2019, 10 :785

[4] Association of Lipidomic Profiles With Progression of Carotid Artery Atherosclerosis in HIV Infection [J].

Chai, Jin Choul ;

Deik, Amy A. ;

Hua, Simin ;

Wang, Tao ;

Hanna, David B. ;

Xue, Xiaonan ;

Haberlen, Sabina A. ;

Shah, Sanjiv J. ;

Suh, Yousin ;

Lazar, Jason M. ;

Gustafson, Deborah ;

Hodis, Howard N. ;

Landay, Alan L. ;

Anastos, Kathryn ;

Post, Wendy S. ;

Kaplan, Robert C. ;

Clish, Clary B. ;

Qi, Qibin .

JAMA CARDIOLOGY, 2019, 4 (12) :1239-1249

[5] TBtools: An Integrative Toolkit Developed for Interactive Analyses of Big Biological Data [J].

Chen, Chengjie ;

Chen, Hao ;

Zhang, Yi ;

Thomas, Hannah R. ;

Frank, Margaret H. ;

He, Yehua ;

Xia, Rui .

MOLECULAR PLANT, 2020, 13 (08) :1194-1202

[6] Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis [J].

Crowson, Cynthia S. ;

Rollefstad, Silvia ;

Ikdahl, Eirik ;

Kitas, George D. ;

van Riel, Piet L. C. M. ;

Gabriel, Sherine E. ;

Matteson, Eric L. ;

Kvien, Tore K. ;

Douglas, Karen ;

Sandoo, Aamer ;

Arts, Elke ;

Wallberg-Jonsson, Solveig ;

Innala, Lena ;

Karpouzas, George ;

Dessein, Patrick H. ;

Tsang, Linda ;

El-Gabalawy, Hani ;

Hitchon, Carol ;

Pascual Ramos, Virginia ;

Contreras Yanez, Irazu ;

Sfikakis, Petros P. ;

Zampeli, Evangelia ;

Gonzalez-Gay, Miguel A. ;

Corrales, Alfonso ;

van de laar, Mart ;

Vonkeman, Harald E. ;

Meek, Inger ;

Samb, Anne Grete .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (01) :48-54

[7] Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort [J].

Croxford, Sara ;

Kitching, Aileen ;

Desai, Sarika ;

Kall, Meaghan ;

Edelstein, Michael ;

Skingsley, Andrew ;

Burns, Fiona ;

Copas, Andrew ;

Brown, Alison E. ;

Sullivan, Ann K. ;

Delpech, Valerie .

LANCET PUBLIC HEALTH, 2017, 2 (01) :E35-E46

[8] General cardiovascular risk profile for use in primary care - The Framingham Heart Study [J].

D'Agostino, Ralph B. ;

Vasan, Ramachandran S. ;

Pencina, Michael J. ;

Wolf, Philip A. ;

Cobain, Mark ;

Massaro, Joseph M. ;

Kannel, William B. .

CIRCULATION, 2008, 117 (06) :743-753

[9] The end of AIDS: HIV infection as a chronic disease [J].

Deeks, Steven G. ;

Lewin, Sharon R. ;

Havlir, Diane V. .

LANCET, 2013, 382 (9903) :1525-1533

[10] STEM: a tool for the analysis of short time series gene expression data [J].

Ernst, J ;

Bar-Joseph, Z .

BMC BIOINFORMATICS, 2006, 7 (1)

← 1 2 3 4 5 →